Illumina has announced a research collaboration with the National Cancer Center Singapore (NCCS) to study the genomics of lymphoma among Asians.
Under the research agreement, the partners will use Illumina’s genome sequencing technology platforms, such as the NovaSeq 6000 to profile the genomes of young adult lymphoma patients from an Asian multiethnic cohort. The research is aimed toward helping in the diagnosis and treatment of the disease, including over 1,000 patients in Singapore.
Analyst QuickTake: In early 2022, San Diego-based Illumina began working with the National Cancer Center Japan on a study of genomics of nasopharyngeal carcinoma in Asian patients. In this study, Illumina used its TruSight Oncology 500 ctDNA to do a genomic analysis of blood samples of up to 96 patients with nasopharynx cancer. The project was initiated as a part of a collaborative study under the Asian Clinical Trials Network for Cancers (ATLAS) project.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.